Recombinant Human Vimentin (Recombinant Human Vimentin; rHuVimentin);重组人波形蛋白
Synonyms
VIM; FLJ36605; vimentin
Purity
>95% by SDS-PAGE and HPLC analyses.
Biological Activity
Data not available.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered solution in 30% Acetonitrile and 0.1% TFA.
Endotoxin
Less than 0.1EU/μg of rHuVimentin as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in 4mM HCl to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Others
Background
Vimentin is a type III intermediate filament (IF) protein that is the major cytoskeletal component of mesenchymal cells, so it is often used as a marker of mesenchymally-derived cells or cells undergoing an epithelial-to-mesenchymal transition (EMT) during both normal development and metastatic progression. Vimentin is a homopolymer assembled from elementary dimers which is mediated by the central alpha-helical coiled-coil rod region. Vimentin plays a significant role in supporting and anchoring the position of the organelles in the cytosol and it is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally. Also, vimentin is found to control the transport of low-density lipoprotein, LDL, -derived cholesterol from alysosome to the site of esterification. Recombinant human vimentin contains 465 amino acid residues and it shares 97%a.a. sequence identity with murine and rat vimentin.